WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H526741
CAS#: 209984-57-6
Description: LY 411575, also known as LSN-411575, is potent, cell permeable and selective γ-secretase inhibitor that reduces Aβ/42 after acute or chronic treatment, and blocks Notch activation. The gamma secretase inhibitor, activating pPKC alpha intracellular pathway could be suggested to prevent or reduce downstream toxic events, representing a useful strategy to counteract Alzheimer's disease.
Hodoodo Cat#: H526741
Name: LY-411575
CAS#: 209984-57-6
Chemical Formula: C26H23F2N3O4
Exact Mass: 479.17
Molecular Weight: 479.484
Elemental Analysis: C, 65.13; H, 4.84; F, 7.92; N, 8.76; O, 13.35
Synonym: LY 411575; LY-411575; LY411575; LSN-411575; LSN 411575; LSN411575.
IUPAC/Chemical Name: N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide
InChi Key: ULSSJYNJIZWPSB-CVRXJBIPSA-N
InChi Code: InChI=1S/C26H23F2N3O4/c1-14(29-25(34)23(32)15-11-16(27)13-17(28)12-15)24(33)30-22-20-9-4-3-7-18(20)19-8-5-6-10-21(19)31(2)26(22)35/h3-14,22-23,32H,1-2H3,(H,29,34)(H,30,33)/t14-,22-,23-/m0/s1
SMILES Code: C[C@@H](C(N[C@H]1C2=CC=CC=C2C3=CC=CC=C3N(C)C1=O)=O)NC([C@H](C4=CC(F)=CC(F)=C4)O)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 479.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Liu-Seifert H, Siemers E, Price K, Han B, Selzler KJ, Henley D, Sundell K, Aisen P, Cummings J, Raskin J, Mohs R; Alzheimer’s Disease Neuroimaging Initiative. Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease. J Alzheimers Dis. 2015;47(1):205-14. doi: 10.3233/JAD-142508. PubMed PMID: 26402769; PubMed Central PMCID: PMC4923754.
2: Ran Y, Ladd GZ, Ceballos-Diaz C, Jung JI, Greenbaum D, Felsenstein KM, Golde TE. Differential Inhibition of Signal Peptide Peptidase Family Members by Established γ-Secretase Inhibitors. PLoS One. 2015 Jun 5;10(6):e0128619. doi: 10.1371/journal.pone.0128619. eCollection 2015. PubMed PMID: 26046535; PubMed Central PMCID: PMC4457840.
3: De Strooper B. Lessons from a failed γ-secretase Alzheimer trial. Cell. 2014 Nov 6;159(4):721-6. doi: 10.1016/j.cell.2014.10.016. PubMed PMID: 25417150.
4: De Strooper B, Chávez Gutiérrez L. Learning by failing: ideas and concepts to tackle γ-secretases in Alzheimer's disease and beyond. Annu Rev Pharmacol Toxicol. 2015;55:419-37. doi: 10.1146/annurev-pharmtox-010814-124309. Epub 2014 Oct 1. Review. PubMed PMID: 25292430.
5: Liu Q, Waltz S, Woodruff G, Ouyang J, Israel MA, Herrera C, Sarsoza F, Tanzi RE, Koo EH, Ringman JM, Goldstein LS, Wagner SL, Yuan SH. Effect of potent γ-secretase modulator in human neurons derived from multiple presenilin 1-induced pluripotent stem cell mutant carriers. JAMA Neurol. 2014 Dec;71(12):1481-9. doi: 10.1001/jamaneurol.2014.2482. PubMed PMID: 25285942; PubMed Central PMCID: PMC4374637.
6: Henley DB, Sundell KL, Sethuraman G, Dowsett SA, May PC. Safety profile of semagacestat, a gamma-secretase inhibitor: IDENTITY trial findings. Curr Med Res Opin. 2014 Oct;30(10):2021-32. doi: 10.1185/03007995.2014.939167. Epub 2014 Jul 14. PubMed PMID: 24983746.
7: Fowler SW, Chiang AC, Savjani RR, Larson ME, Sherman MA, Schuler DR, Cirrito JR, Lesné SE, Jankowsky JL. Genetic modulation of soluble Aβ rescues cognitive and synaptic impairment in a mouse model of Alzheimer's disease. J Neurosci. 2014 Jun 4;34(23):7871-85. doi: 10.1523/JNEUROSCI.0572-14.2014. Erratum in: J Neurosci. 2014 Dec 10;34(50):16917. PubMed PMID: 24899710; PubMed Central PMCID: PMC4044248.
8: Yesuvadian R, Krishnamoorthy J, Ramamoorthy A, Bhunia A. Potent γ-secretase inhibitors/modulators interact with amyloid-β fibrils but do not inhibit fibrillation: a high-resolution NMR study. Biochem Biophys Res Commun. 2014 May 16;447(4):590-5. doi: 10.1016/j.bbrc.2014.04.041. Epub 2014 Apr 18. PubMed PMID: 24747079.
9: Bramhall NF, Shi F, Arnold K, Hochedlinger K, Edge AS. Lgr5-positive supporting cells generate new hair cells in the postnatal cochlea. Stem Cell Reports. 2014 Feb 20;2(3):311-22. doi: 10.1016/j.stemcr.2014.01.008. eCollection 2014 Mar 11. PubMed PMID: 24672754; PubMed Central PMCID: PMC3964281.
10: Henley DB, Sundell KL, Sethuraman G, Schneider LS. Adverse events and dropouts in Alzheimer's disease studies: what can we learn? Alzheimers Dement. 2015 Jan;11(1):24-31. doi: 10.1016/j.jalz.2013.11.008. Epub 2014 Mar 6. PubMed PMID: 24613705.
11: Beggiato S, Giuliani A, Sivilia S, Lorenzini L, Antonelli T, Imbimbo BP, Giardino L, Calzà L, Ferraro L. CHF5074 and LY450139 sub-acute treatments differently affect cortical extracellular glutamate levels in pre-plaque Tg2576 mice. Neuroscience. 2014 Apr 25;266:13-22. doi: 10.1016/j.neuroscience.2014.01.065. Epub 2014 Feb 12. PubMed PMID: 24530449.
12: Ito G, Okamoto R, Murano T, Shimizu H, Fujii S, Nakata T, Mizutani T, Yui S, Akiyama-Morio J, Nemoto Y, Okada E, Araki A, Ohtsuka K, Tsuchiya K, Nakamura T, Watanabe M. Lineage-specific expression of bestrophin-2 and bestrophin-4 in human intestinal epithelial cells. PLoS One. 2013 Nov 5;8(11):e79693. doi: 10.1371/journal.pone.0079693. eCollection 2013. PubMed PMID: 24223998; PubMed Central PMCID: PMC3818177.
13: Wang Y, Ahmad AA, Shah PK, Sims CE, Magness ST, Allbritton NL. Capture and 3D culture of colonic crypts and colonoids in a microarray platform. Lab Chip. 2013 Dec 7;13(23):4625-34. doi: 10.1039/c3lc50813g. PubMed PMID: 24113577; PubMed Central PMCID: PMC3841105.
14: Blennow K, Zetterberg H, Haass C, Finucane T. Semagacestat's fall: where next for AD therapies? Nat Med. 2013 Oct;19(10):1214-5. doi: 10.1038/nm.3365. PubMed PMID: 24100981.
15: Trechot P, Schmutz JL. [Exacerbation of psoriasiform lesions by a gamma-secretase inhibitor]. Ann Dermatol Venereol. 2013 Oct;140(10):669-70. doi: 10.1016/j.annder.2013.06.003. Epub 2013 Jul 29. French. PubMed PMID: 24090904.
16: Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, He F, Sun X, Thomas RG, Aisen PS; Alzheimer's Disease Cooperative Study Steering Committee, Siemers E, Sethuraman G, Mohs R; Semagacestat Study Group. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med. 2013 Jul 25;369(4):341-50. doi: 10.1056/NEJMoa1210951. PubMed PMID: 23883379.
17: Winston CN, Chellappa D, Wilkins T, Barton DJ, Washington PM, Loane DJ, Zapple DN, Burns MP. Controlled cortical impact results in an extensive loss of dendritic spines that is not mediated by injury-induced amyloid-beta accumulation. J Neurotrauma. 2013 Dec 1;30(23):1966-72. doi: 10.1089/neu.2013.2960. Epub 2013 Oct 12. PubMed PMID: 23879560; PubMed Central PMCID: PMC3837436.
18: Haug KG, Staab A, Dansirikul C, Lehr T. A semi-physiological model of amyloid-β biosynthesis and clearance in human cerebrospinal fluid: a tool for alzheimer's disease research and drug development. J Clin Pharmacol. 2013 Jul;53(7):691-8. doi: 10.1002/jcph.91. Epub 2013 May 27. PubMed PMID: 23712554.
19: Schellekens H, McNamara O, Dinan TG, McCarthy JV, McGlacken GP, Cryan JF. Semagacestat, a γ-secretase inhibitor, activates the growth hormone secretagogue (GHS-R1a) receptor. J Pharm Pharmacol. 2013 Apr;65(4):528-38. doi: 10.1111/jphp.12010. Epub 2012 Nov 27. PubMed PMID: 23488781.
20: Grotek B, Wehner D, Weidinger G. Notch signaling coordinates cellular proliferation with differentiation during zebrafish fin regeneration. Development. 2013 Apr;140(7):1412-23. doi: 10.1242/dev.087452. Epub 2013 Mar 5. PubMed PMID: 23462472.
